Drug
MaaT013
MaaT013 is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
1
33%
Ph phase_3
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 3Large-scale testing
1(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Other(1)
Detailed Status
unknown1
Active, not recruiting1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (50.0%)
Phase 31 (50.0%)
Trials by Status
unknown133%
active_not_recruiting133%
completed133%
Recent Activity
1 active trials
Showing 3 of 3
completedphase_2
Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma
NCT04988841
active_not_recruitingphase_3
MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients
NCT04769895
unknown
Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease
NCT04768907
Clinical Trials (3)
Showing 3 of 3 trials
NCT04988841Phase 2
Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma
NCT04769895Phase 3
MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients
NCT04768907
Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3